Export

Biotech floats come back with a vengeance

Date July 05, 2017

If as recently as three months ago biotech flotations looked like an area in terminal decline, the second quarter witnessed a remarkable turnaround, with the total raised in new issues exceeding $1bn and amounting to the strongest IPO quarter since nearly two years ago.

The resurgence has been driven by the US, which in Biohaven’s $168m float saw the biggest IPO of 2017 so far. It will not go unnoticed that the third quarter of 2015, the last time the $1bn mark was breached, came just after the peak of biotech’s bull run, and that the Nasdaq biotech index last month hit its highest point since the end of 2015 (see data below).

The second-quarter numbers provide a neat contrast with the climate for acquisitions, which the latest data suggest appears to have stalled (Second-quarter deals show a sector set on pause, July 3, 2017).

The valuation question

Since big pharma is not thought to have stopped looking for takeover targets, this trend suggests a divergence of opinions about biotech valuations.

As long as big pharma is sceptical of the surging market caps of potential targets M&A deal-making will remain subdued. For biotech this is not a problem – as long as small companies can, as the IPO numbers suggest, attract significant cash from public and VC investors their argument for holding out against what they perceive to be undervalued bids will remain strong.

Biohaven is a case in point: the group, focused on the trendy area of genetic diseases, had raised over $100m since inception four years ago, and capped that with a premium-priced $168m float, which amounted to $194m gross if the overallotment option is included. Not only that, but since floating its stock has put on 47%.

Q2 biotech IPOs on Western exchanges (Nasdaq unless stated) 
Company  Date  Amount raised ($m)  Offering price ($)  Premium/(discount)  First-day close ($)  Q2 chg since float 
Biohaven Pharmaceutical (NYSE)  04 May  168  17.00  13%  17.50  47% 
G1 Therapeutics  17 May  105  15.00  (6%)  15.00  16% 
Tocagen  13 Apr  85  10.00  (9%)  12.45  20% 
Athenex  14 Jun  76  11.00  (8%)  12.56  45% 
Dova Pharmaceuticals  29 Jun  75  17.00  6%  19.81  31% 
Ovid Therapeutics  05 May  75  15.00  (6%)  12.25  (30%) 
Mersana Therapeutics  28 Jun  75  15.00  0%  14.00  (7%) 
Zymeworks (NYSE)  28 Apr  64  13.00  (10%)  13.00  (36%) 
Urogen Pharma  04 May  58  13.00  8%  13.98  39% 
Aileron Therapetuics  29 Jun  56  15.00  (6%)  10.80  (26%) 
Bergenbio (OSE)  07 Apr  51  2.90  –  25.00  (13%) 
Isofol Medical (Nasdaq First North)  04 Apr  48  3.22  –  27.00  (20%) 
Valbiotis (Euronext)  07 Jun  40  11.80  0%  10.00  (4%) 
Avenue Therapeutics  27 Jun  38  6.00  0%  8.25  33% 
Skinbiotherapeutics (LSE)  05 Apr  11.23  –  15.00  23% 
Annexin Pharmaceuticals (Nasdaq First North)  19 Apr  17.67  –  8.40  (50%) 

The company was one of 16 biotechs that floated in the second quarter, only five of which did not involve US exchanges. In the previous three months Nasdaq was looking like a very unfriendly place, with half the first-quarter IPOs being done on European exchanges.

Arguably, two of the second-quarter entrants were not fully fledged IPOs; Skinbiotherapeutics and Avenue Therapeutics are both spin-outs of bigger biotechs, Optibiotix Health and Fortress Bio respectively. Optibiotix retains a 42% Skinbiotherapeutics stake, while Fortress has majority control of Avenue by virtue of class A preferred stock.

It will come as no surprise that non-US floats ended up at the bottom of the second-quarter table in terms of IPO size. Perhaps more worryingly, it was also non-US biotechs that accounted for the lion’s share of post-float share price declines – four of seven – and collectively this cohort is off 13%.

Though pre-IPO price haircuts are still commonplace, the fact that the second quarter suggested a relative equilibration of entrants might please biotechs in the flotation queue: two raised over $100m (the oncology player G1 Therapeutics in addition to Biohaven), yet the average amount raised, at $63m, outstripped the $51m average of 2016.

Renaissance Capital, a provider of IPO and pre-IPO analysis, last week found that across all sectors the second quarter of 2017 provided the most active US IPO market for two years. And it was tech and healthcare that drove this mini bull market, at the expense of natural resources companies.

Those hoping for continued resilience from biotech as the markets enter the summer lull will hope that this is just the beginning.

To contact the writers of this story email Jacob Plieth or Edwin Elmhirst in London at news@epvantage.com or follow  @JacobPlieth or @EdwinElmhirst on Twitter

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2017 EP Vantage Ltd